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patients were still alive. For these patients, the survival was calculated 
until March 8, 2007. 
Results: Between October 2001 and December 2006, a total of 46 
NSCLC patients were treated. Two patients were not evaluable because 
we could not ﬁnd his data ﬁle. Characteristics of patients were as fol-
lows: Median age 56 years (range 41-72), male 41, female 3 and PS 0 
= 7 / 1 = 37. Histologic diagnosis was adenocarcinoma in 17 patients, 
squamous cell carcinoma in 5 and undifferentiated NSCLC in 22. 
Brain metastasis were present 7 patients (16%) prior starting the treat-
ment. Median number of cycles were 3.0 (range 1-6). In 45 evaluable 
patients, complete responses were seen in 1 patient ( 2.3%), partial 
response in 15 (34.1%) and disease stabilization in 19 ( 43.2%). In total 
of 140 cycles, grade 3-4 neutropenia, grade 3-4 leukopenia and grade 
3-4 anemia occured in 16.5%, 10% and 0.7% respectively. One fatal 
event was observed. The median survival was 285 days (95% CI [172-
397]) and at 1 and 2 years survival were 39% and 9.5%, respectively.
Conclusion: The combination of cisplatin plus vinorelbine is an active 
and tolerable regimen in Turkish patients with metastatic NSCLC.
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Background: Single-agent chemotherapy has been considered as 
standard treatment for elderly patients with non-small cell lung cancer 
(NSCLC). However recent subset analyses suggest that platinum-
based combination chemotherapy may be safely administered to the 
elderly with good performance status (PS). We evaluated the efﬁcacy 
and safety of carboplatin and docetaxel in a phase II study of elderly 
patients aged 70 years or older.
Methods: Chemotherapy-naive patients aged ≥70 years with advanced 
NSCLC (IIIB-IV), ECOG performance status (PS) of 0-2, a measurable 
lesion, and adequate organ functions were enrolled. Patients received 
carboplatin (AUC 5) and docetaxel (60 mg/m2) administered on day 
1 every 3 weeks. The primary endpoint was response rate (RR). This 
study, with a planned sample size of 25, had 80% power to support the 
hypothesis that the true RR was >30%, and 5% signiﬁcance to deny the 
hypothesis that the true RR was <10%. 
Results: Between October 2003 and April 2006, 30 elderly patients 
with NSCLC were enrolled in the study and all patients were treated. 
Demographics: M/F 20/10; PS 0/1/2 2/23/5; median age 75 (range 70-
84). Median number of treatment cycles was 3.5. Responses in the 30 
evaluable patients included 1CR; 13PR; for an objective RR of 46.7% 
(95%CI 28.8-64.6%). By January 4, 2007, 21 (70.0%) of 30 patients 
had died. Median follow-up for survival was 8.4 months. The median 
time to tumor progression was 4.4 months, and the median survival was 
9.9 months. The 1-year survival rate was 43.3%.Grade 3/4 hematologic 
toxicities included leukopenia (80.0%), neutropenia (86.7%), anemia 
(16.7%) and thrombocytopenia (3.3%). Non-hematologic toxicities 
were mild with no grade 4 toxicities; grade 3 nausea (10.0%), anorexia 
(30.0%), diarrhea (13.3%), fatigue (6.7%), allergic reaction (6.7%), 
pneumonitis (3.3%), febril neutropenia (16.7%) and infection (10.0%) 
were observed. 
Conclusion: The combination of carboplatin and docetaxel was safe 
and promising for the treatment of chemotherapy-naive elderly patients 
with advanced NSCLC. This regimen warrants further evaluation in a 
phase III trial.
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Outcome of patients with stage III and IV non-small cell lung 
cancer in Marmara University Hospital, Istanbul, Turkey
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Background: Lung Cancer is one of the ﬁve most diagnosed cancers in 
Turkey. Treatment outcomes of 353 patients with advanced or metastat-
ic NSCLC who were treated in Marmara University Oncology Clinics 
between April 1997 and March 2007 were evaluated. 
Methods: All patients were diagnosed histologically or cytologically 
and staged with CAT scans. Patients with WHO performance status 
(PS) 2 and lower received chemotherapy (CT). A platinum analogue 
was used in combination with etoposide, vinorelbine, gemcitabine or 
taxanes as the ﬁrst line treatment in 83% patients. Elderly (65 years and 
older) or patients with poor PS (PS=2) were treated with single agent 
CT. Three to 6 cycles of treatment was administered depending on 
clinical or radiological response. Radiation therapy to primary tumor 
was administered to stage III patients after completion of ﬁrst line CT 
and to symptomatic stage IV patients for palliation. Eligible stage IIIA 
patients (16%) were operated. Second line treatment was offered to 
patients with progressive disease for 3 to 6 cycles. 
Results: Median age was 60 years (range: 29-87) and 80% of pa-
tients were male. Histological subtypes were squamous cell in 33%, 
adenocarcinoma in 35%, NSCLC in 30% and large cell cancer 2%. PS 
was 0 in 53% of the patients. Fifteen percent of the patients were stage 
IIIA, 22% were stage IIIB, and 63% were stage IV. The median number 
of cycles administered was 3. At a median follow-up was 11 months 
(range 1-82), 71% of patients died. Median overall survival (OS) was 
14 months, 1-year and 2-year OS ratios were 54% and 27%, respective-
ly. Median time to progression (TTP) was 5 months; 1-year progres-
sion free survival (PFS) ratio was 16%. Women, patients with stage III 
disease, and PS 0 or 1 lived signiﬁcantly longer (p=0.01, p=0.03, and 
p<0.001, respectively). Age, histology, smoking history or type of CT 
didn’t have any statistically signiﬁcant effect on survival in univari-
ate analysis. Only stage had an impact on OS in multivariate analysis. 
Stage was also the only factor on PFS (p<0.001). 
Conclusions: Advanced staged NSCLC patients has poor prognosis. 
Our results are consistent with the world literature.
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Background: Although Taxane is widely used for various types of 
cancer for lung cancer treatment, it is used for no more than ﬁve years. 
Thus, there is not enough data on survival beneﬁt of this new agent. 
In order to investigate the impact of Taxane in the survival of patients 
with NSCLC, a multi-centre retrospective investigation was conducted 
between 1st January 1995 and 31st December 2006. 
Methods: Two groups of patients were included: Group A consisted 
of 403 patients (338 males and 45 females), median 61,00 ± 0.41 
years, treated with Docetaxel (D) in a dose of 100mg/m2 in a two-hour 
infusion, combined with Carboplatin (C) in a dose of AUC = 5.5 in a 
four-week interval up to 8 cycles. Group A consisted of 288 patients 
(266 males and 22 females), median 62 ± 0.47 years, treated with a 
variety of chemotherapeutic agents including Carboplatin in the same 
dose as in group A, following the same number and cycle interval. No 
statistically signiﬁcant differences were observed in age, histological 
type, performance status and TNM staging between the two investi-
gated groups. 
Results: The table shows the median survival in each group of patients. 
Kaplan Mayer method was used to estimate survival curves and log 
rank correlation to check for statistical difference between the two 
groups. 
 N Survival (in days) P
  Median ± SEM (95% CI) (log rank)
Group A 403 356 ±19.3 (318 - 393.9)  
Group B (all cases) 288 250 ± 15.3 (287.4 - 342.5)  
Group A 197 411 ± 40.5 (331.6 - 490) 0.047
Group B (stage IIIb) 173 286 ± 31 (224.6 - 347)  
Group A 206 299 ± 20 (259 - 338.7) 0.007
Group B (stage IV) 115 203 ±26 (151 - 254.7)
A statistical signiﬁcant increase in patients’ survival of group A was 
observed compared to group B, especially in patients of stage IV. More-
over, an increase in survival of group A was observed in stage IIIB, but 
at the limits of signiﬁcancy. 
Conclusion: It seems that D administration increases survival in 
patients with NSCLC especially in stage IV. On the other hand, in stage 
IIIb the survival beneﬁt is at the limits of signiﬁcancy.
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Objective: Recent trials have shown signiﬁcant survival beneﬁt from 
adjuvant chemotherapy after resection of NSCLC. Whether elderly 
patients tolerate platinum-based adjuvant chemotherapy and derive 
the same survival advantage is unknown. This retrospective study 
evaluated the inﬂuence of age on survival, chemotherapy delivery and 
toxicity. 
Methods: Pretreatment characteristics, follow up data and survival 
beneﬁt from treatment were collected. Chemotherapy delivery, toxicity 
1-year survival and disease control rate (DCR) were compared for 99 
treated patients. 
Results: There were 99 elderly patients who were over 75 years. 
Overall DCR was 83%, that for monotherapy, two-drug and three-drug 
were 66.7%, 81% and 91%, respectively. 1-year survival rate was 
38%,15%,25% and 66%, respectively. The toxicity was tolerable. 
Conclusions: chemotherapy improves overall survival in patients aged 
over 75 years with acceptable toxicity. chemotherapy should not be 
withheld from elderly patients.
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Objectives: To investigate the expression of extracellular matrix in 
neo-adjuvant chemotherapy and control group, and its relationship with 
clinical signiﬁcance in non-small cell lung cancer. 
Methods: Expression of extracellular matrix in lung cancer tissues 
was detected in 73 patients by using immunohistochemistry Envision 
method. 
Results: The median survival of 14 patients with low expression of 
ﬁbronetin was 67month, 57 patients with positive expression was 
38month. A signiﬁcant difference existed between the two groups 
(P=0.048). The high expression of laminin in neo-adjuvant chemother-
apy group were negatively related to clinical response.When analyzed 
only patients randomized to neo-ajuvant chemotherapy using cox step-
wise regression analysis, the TNM stage is the only prognosis factor to 
survival. 
Conclusion: Overexpression of some extracellular matrix may be 
involved in the negative chemoresponse rate. The survival time of 
ﬁbronectin and laminin negative patients may be longer than positive 
patients.
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Objective: To investigate efﬁcacy and safety of ﬁrst-line chemo-
therapy of vinorelbine/cisplatin (NP) combined with cyclooxygenase-2 
inhibitor celecoxib in advanced non-small-cell lung cancer (NSCLC) 
patients. 
Methods: 65 NSCLC patients were randomly assigned to Arm A or B. 
In the arm A, 32 patients were treated with vinorelbine 25mg/m2 iv on 
days 1 and 8, cisplatin 75mg/m2 iv on day 1 and celecoxib 400mg bid 
po on days 1 to 12, repeated every 21 days. In the arm B, 33 cases were 
treated with NP regimen alone. 
Results: Compared with arm B, the response rate in arm A was 
35.5% vs 26.7%(P=0.457), disease control rate was 87.1% vs 
66.7%(P=0.058), one-year survival rate was 58.1% vs 36.7%(P=0.094) 
and median survival time was 12 months vs 9.2 months 
(P=0.062)respectively. Subgroup analysis showed that in the 36 adeno-
